CAR T-Cell therapy Market By Drug type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), By Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), By End user (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. During this treatment, healthcare professionals reprogram the immune system to attack cancer cells. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors. Healthcare professionals currently use CAR T-cell therapy to treat various types of cancer.

The CAR T-cell therapy market will show significant market growth during the forecast period owing to rise in prevalence of cancer, rise in demand for ideal therapeutics for treatment of cancer, and favorable reimbursement policies provided by manufacturers & insurance providers in some countries. However, higher cost of treatment, and stringent government regulation for approval of these therapeutics are expected to hamper the market growth. Furthermore, promising drugs in pipeline, expected approval of newer CART therapeutics, rise in number of target population with lack of ideal treatment, and surge in awareness regarding CART therapies are expected to significantly drive the market growth during the forecast period. In addition, technological advancements, launch of various products, and strategies among the key players such as acquisition, collaboration, and agreement drive the CAR T-cell therapy market growth.

The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.

The CAR T-cell therapy market is studied across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

The major players profiled in the report are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the car t-cell therapy market analysis from 2021 to 2031 to identify the prevailing car t-cell therapy market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global car t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

By Indication

● Lymphoma

● Acute Lymphocytic Leukemia

● Others

By End user

● Hospitals

● Cancer Treatment Centers

By Drug type

● Axicabtagene Ciloleucel

● Tisagenlecleucel

● Brexucabtagene Autoleucel

● Others

By Region

● North America

○ U.S.

○ Canada

● Europe

○ Germany

○ France

○ U.K.

○ Rest of Europe

● Asia-Pacific

○ Japan

○ China

○ Rest of Asia-Pacific

● LAMEA

○ Latin America

○ Middle East And Africa

● Key Market Players

○ Autolus Therapeutics

○ Bluebird bio, Inc.

○ Bristol-Myers Squibb

○ Caribou Biosciences, Inc.

○ Cartesian Therapeutics, Inc.

○ Celgene Corporation

○ Cellectis

○ Celyad Oncology

○ Gilead Sciences, Inc. (Kite Pharma Inc.)

○ Intellia Therapeutics

○ Juno Therapeutics, Inc.

○ Merck & Co., Inc.

○ Miltenyi Biotech

○ Novartis AG

○ Pfizer, Inc.

○ Sorrento Therapeutics, Inc

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Axicabtagene Ciloleucel

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Tisagenlecleucel

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Brexucabtagene Autoleucel

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Others

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Lymphoma

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Acute Lymphocytic Leukemia

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospitals

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Cancer Treatment Centers

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Drug type

7.2.3 North America Market size and forecast, by Indication

7.2.4 North America Market size and forecast, by End user

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Drug type

7.2.5.1.2 Market size and forecast, by Indication

7.2.5.1.3 Market size and forecast, by End user

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Drug type

7.2.5.2.2 Market size and forecast, by Indication

7.2.5.2.3 Market size and forecast, by End user

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Drug type

7.3.3 Europe Market size and forecast, by Indication

7.3.4 Europe Market size and forecast, by End user

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Drug type

7.3.5.1.2 Market size and forecast, by Indication

7.3.5.1.3 Market size and forecast, by End user

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Drug type

7.3.5.2.2 Market size and forecast, by Indication

7.3.5.2.3 Market size and forecast, by End user

7.3.5.3 U.K.

7.3.5.3.1 Market size and forecast, by Drug type

7.3.5.3.2 Market size and forecast, by Indication

7.3.5.3.3 Market size and forecast, by End user

7.3.5.4 Rest of Europe

7.3.5.4.1 Market size and forecast, by Drug type

7.3.5.4.2 Market size and forecast, by Indication

7.3.5.4.3 Market size and forecast, by End user

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Drug type

7.4.3 Asia-Pacific Market size and forecast, by Indication

7.4.4 Asia-Pacific Market size and forecast, by End user

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Drug type

7.4.5.1.2 Market size and forecast, by Indication

7.4.5.1.3 Market size and forecast, by End user

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Drug type

7.4.5.2.2 Market size and forecast, by Indication

7.4.5.2.3 Market size and forecast, by End user

7.4.5.3 Rest of Asia-Pacific

7.4.5.3.1 Market size and forecast, by Drug type

7.4.5.3.2 Market size and forecast, by Indication

7.4.5.3.3 Market size and forecast, by End user

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Drug type

7.5.3 LAMEA Market size and forecast, by Indication

7.5.4 LAMEA Market size and forecast, by End user

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Latin America

7.5.5.1.1 Market size and forecast, by Drug type

7.5.5.1.2 Market size and forecast, by Indication

7.5.5.1.3 Market size and forecast, by End user

7.5.5.2 Middle East And Africa

7.5.5.2.1 Market size and forecast, by Drug type

7.5.5.2.2 Market size and forecast, by Indication

7.5.5.2.3 Market size and forecast, by End user

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Autolus Therapeutics

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Bluebird bio, Inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Bristol-Myers Squibb

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Caribou Biosciences, Inc.

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Cartesian Therapeutics, Inc.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Celgene Corporation

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Cellectis

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Celyad Oncology

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Gilead Sciences, Inc. (Kite Pharma Inc.)

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Intellia Therapeutics

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and developments

9.11 Juno Therapeutics, Inc.

9.11.1 Company overview

9.11.2 Company snapshot

9.11.3 Operating business segments

9.11.4 Product portfolio

9.11.5 Business performance

9.11.6 Key strategic moves and developments

9.12 Merck & Co., Inc.

9.12.1 Company overview

9.12.2 Company snapshot

9.12.3 Operating business segments

9.12.4 Product portfolio

9.12.5 Business performance

9.12.6 Key strategic moves and developments

9.13 Miltenyi Biotech

9.13.1 Company overview

9.13.2 Company snapshot

9.13.3 Operating business segments

9.13.4 Product portfolio

9.13.5 Business performance

9.13.6 Key strategic moves and developments

9.14 Novartis AG

9.14.1 Company overview

9.14.2 Company snapshot

9.14.3 Operating business segments

9.14.4 Product portfolio

9.14.5 Business performance

9.14.6 Key strategic moves and developments

9.15 Pfizer, Inc.

9.15.1 Company overview

9.15.2 Company snapshot

9.15.3 Operating business segments

9.15.4 Product portfolio

9.15.5 Business performance

9.15.6 Key strategic moves and developments

9.16 Sorrento Therapeutics, Inc.

9.16.1 Company overview

9.16.2 Company snapshot

9.16.3 Operating business segments

9.16.4 Product portfolio

9.16.5 Business performance

9.16.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 2. CAR T-CELL THERAPY MARKET SIZE, FOR AXICABTAGENE CILOLEUCEL, BY REGION, 2021-2031 ($MILLION)

TABLE 3. CAR T-CELL THERAPY MARKET FOR AXICABTAGENE CILOLEUCEL BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. CAR T-CELL THERAPY MARKET SIZE, FOR TISAGENLECLEUCEL, BY REGION, 2021-2031 ($MILLION)

TABLE 5. CAR T-CELL THERAPY MARKET FOR TISAGENLECLEUCEL BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. CAR T-CELL THERAPY MARKET SIZE, FOR BREXUCABTAGENE AUTOLEUCEL, BY REGION, 2021-2031 ($MILLION)

TABLE 7. CAR T-CELL THERAPY MARKET FOR BREXUCABTAGENE AUTOLEUCEL BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. CAR T-CELL THERAPY MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 9. CAR T-CELL THERAPY MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)

TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 11. CAR T-CELL THERAPY MARKET SIZE, FOR LYMPHOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 12. CAR T-CELL THERAPY MARKET FOR LYMPHOMA BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. CAR T-CELL THERAPY MARKET SIZE, FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)

TABLE 14. CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA BY COUNTRY, 2021-2031 ($MILLION)

TABLE 15. CAR T-CELL THERAPY MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 16. CAR T-CELL THERAPY MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. GLOBAL CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 18. CAR T-CELL THERAPY MARKET SIZE, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)

TABLE 19. CAR T-CELL THERAPY MARKET FOR HOSPITALS BY COUNTRY, 2021-2031 ($MILLION)

TABLE 20. CAR T-CELL THERAPY MARKET SIZE, FOR CANCER TREATMENT CENTERS, BY REGION, 2021-2031 ($MILLION)

TABLE 21. CAR T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS BY COUNTRY, 2021-2031 ($MILLION)

TABLE 22. CAR T-CELL THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 23. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 24. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 25. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 26. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 27. U.S. CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 28. U.S. CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 29. U.S. CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 30. CANADA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 31. CANADA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 32. CANADA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 33. EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 34. EUROPE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 35. EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 36. EUROPE CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 37. GERMANY CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 38. GERMANY CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 39. GERMANY CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 40. FRANCE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 41. FRANCE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 42. FRANCE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 43. U.K. CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 44. U.K. CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 45. U.K. CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 46. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 47. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 48. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 49. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 50. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 51. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 52. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 53. JAPAN CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 54. JAPAN CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 55. JAPAN CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 56. CHINA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 57. CHINA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 58. CHINA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 59. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 60. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 61. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 62. LAMEA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 63. LAMEA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 64. LAMEA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 65. LAMEA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 66. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 67. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 68. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 69. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 70. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 71. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 72.AUTOLUS THERAPEUTICS: COMPANY SNAPSHOT

TABLE 73.AUTOLUS THERAPEUTICS: OPERATING SEGMENTS

TABLE 74.AUTOLUS THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 75.AUTOLUS THERAPEUTICS: NET SALES,

TABLE 76.AUTOLUS THERAPEUTICS: KEY STRATERGIES

TABLE 77.BLUEBIRD BIO, INC.: COMPANY SNAPSHOT

TABLE 78.BLUEBIRD BIO, INC.: OPERATING SEGMENTS

TABLE 79.BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO

TABLE 80.BLUEBIRD BIO, INC.: NET SALES,

TABLE 81.BLUEBIRD BIO, INC.: KEY STRATERGIES

TABLE 82.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 83.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS

TABLE 84.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 85.BRISTOL-MYERS SQUIBB: NET SALES,

TABLE 86.BRISTOL-MYERS SQUIBB: KEY STRATERGIES

TABLE 87.CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT

TABLE 88.CARIBOU BIOSCIENCES, INC.: OPERATING SEGMENTS

TABLE 89.CARIBOU BIOSCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 90.CARIBOU BIOSCIENCES, INC.: NET SALES,

TABLE 91.CARIBOU BIOSCIENCES, INC.: KEY STRATERGIES

TABLE 92.CARTESIAN THERAPEUTICS, INC.: COMPANY SNAPSHOT

TABLE 93.CARTESIAN THERAPEUTICS, INC.: OPERATING SEGMENTS

TABLE 94.CARTESIAN THERAPEUTICS, INC.: PRODUCT PORTFOLIO

TABLE 95.CARTESIAN THERAPEUTICS, INC.: NET SALES,

TABLE 96.CARTESIAN THERAPEUTICS, INC.: KEY STRATERGIES

TABLE 97.CELGENE CORPORATION: COMPANY SNAPSHOT

TABLE 98.CELGENE CORPORATION: OPERATING SEGMENTS

TABLE 99.CELGENE CORPORATION: PRODUCT PORTFOLIO

TABLE 100.CELGENE CORPORATION: NET SALES,

TABLE 101.CELGENE CORPORATION: KEY STRATERGIES

TABLE 102.CELLECTIS: COMPANY SNAPSHOT

TABLE 103.CELLECTIS: OPERATING SEGMENTS

TABLE 104.CELLECTIS: PRODUCT PORTFOLIO

TABLE 105.CELLECTIS: NET SALES,

TABLE 106.CELLECTIS: KEY STRATERGIES

TABLE 107.CELYAD ONCOLOGY: COMPANY SNAPSHOT

TABLE 108.CELYAD ONCOLOGY: OPERATING SEGMENTS

TABLE 109.CELYAD ONCOLOGY: PRODUCT PORTFOLIO

TABLE 110.CELYAD ONCOLOGY: NET SALES,

TABLE 111.CELYAD ONCOLOGY: KEY STRATERGIES

TABLE 112.GILEAD SCIENCES, INC. (KITE PHARMA INC.): COMPANY SNAPSHOT

TABLE 113.GILEAD SCIENCES, INC. (KITE PHARMA INC.): OPERATING SEGMENTS

TABLE 114.GILEAD SCIENCES, INC. (KITE PHARMA INC.): PRODUCT PORTFOLIO

TABLE 115.GILEAD SCIENCES, INC. (KITE PHARMA INC.): NET SALES,

TABLE 116.GILEAD SCIENCES, INC. (KITE PHARMA INC.): KEY STRATERGIES

TABLE 117.INTELLIA THERAPEUTICS: COMPANY SNAPSHOT

TABLE 118.INTELLIA THERAPEUTICS: OPERATING SEGMENTS

TABLE 119.INTELLIA THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 120.INTELLIA THERAPEUTICS: NET SALES,

TABLE 121.INTELLIA THERAPEUTICS: KEY STRATERGIES

TABLE 122.JUNO THERAPEUTICS, INC.: COMPANY SNAPSHOT

TABLE 123.JUNO THERAPEUTICS, INC.: OPERATING SEGMENTS

TABLE 124.JUNO THERAPEUTICS, INC.: PRODUCT PORTFOLIO

TABLE 125.JUNO THERAPEUTICS, INC.: NET SALES,

TABLE 126.JUNO THERAPEUTICS, INC.: KEY STRATERGIES

TABLE 127.MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 128.MERCK & CO., INC.: OPERATING SEGMENTS

TABLE 129.MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 130.MERCK & CO., INC.: NET SALES,

TABLE 131.MERCK & CO., INC.: KEY STRATERGIES

TABLE 132.MILTENYI BIOTECH: COMPANY SNAPSHOT

TABLE 133.MILTENYI BIOTECH: OPERATING SEGMENTS

TABLE 134.MILTENYI BIOTECH: PRODUCT PORTFOLIO

TABLE 135.MILTENYI BIOTECH: NET SALES,

TABLE 136.MILTENYI BIOTECH: KEY STRATERGIES

TABLE 137.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 138.NOVARTIS AG: OPERATING SEGMENTS

TABLE 139.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 140.NOVARTIS AG: NET SALES,

TABLE 141.NOVARTIS AG: KEY STRATERGIES

TABLE 142.PFIZER, INC.: COMPANY SNAPSHOT

TABLE 143.PFIZER, INC.: OPERATING SEGMENTS

TABLE 144.PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 145.PFIZER, INC.: NET SALES,

TABLE 146.PFIZER, INC.: KEY STRATERGIES

TABLE 147.SORRENTO THERAPEUTICS, INC.: COMPANY SNAPSHOT

TABLE 148.SORRENTO THERAPEUTICS, INC.: OPERATING SEGMENTS

TABLE 149.SORRENTO THERAPEUTICS, INC.: PRODUCT PORTFOLIO

TABLE 150.SORRENTO THERAPEUTICS, INC.: NET SALES,

TABLE 151.SORRENTO THERAPEUTICS, INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.CAR T-CELL THERAPY MARKET SEGMENTATION

FIGURE 2.CAR T-CELL THERAPY MARKET,2021-2031

FIGURE 3.CAR T-CELL THERAPY MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.CAR T-CELL THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.CAR T-CELL THERAPY MARKET,BY DRUG TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AXICABTAGENE CILOLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TISAGENLECLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF BREXUCABTAGENE AUTOLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 17.CAR T-CELL THERAPY MARKET,BY INDICATION,2021(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF LYMPHOMA CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ACUTE LYMPHOCYTIC LEUKEMIA CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 21.CAR T-CELL THERAPY MARKET,BY END USER,2021(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CANCER TREATMENT CENTERS CAR T-CELL THERAPY MARKET,2021-2031(%)

FIGURE 24.CAR T-CELL THERAPY MARKET BY REGION,2021

FIGURE 25.U.S. CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 26.CANADA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 27.GERMANY CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 28.FRANCE CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 29.U.K. CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 30.REST OF EUROPE CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 31.JAPAN CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 32.CHINA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 33.REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 34.LATIN AMERICA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 35.MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 36. TOP WINNING STRATEGIES, BY YEAR

FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 40.COMPETITIVE DASHBOARD

FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 42.AUTOLUS THERAPEUTICS.: NET SALES ,($MILLION)

FIGURE 43.BLUEBIRD BIO, INC..: NET SALES ,($MILLION)

FIGURE 44.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)

FIGURE 45.CARIBOU BIOSCIENCES, INC..: NET SALES ,($MILLION)

FIGURE 46.CARTESIAN THERAPEUTICS, INC..: NET SALES ,($MILLION)

FIGURE 47.CELGENE CORPORATION.: NET SALES ,($MILLION)

FIGURE 48.CELLECTIS.: NET SALES ,($MILLION)

FIGURE 49.CELYAD ONCOLOGY.: NET SALES ,($MILLION)

FIGURE 50.GILEAD SCIENCES, INC. (KITE PHARMA INC.).: NET SALES ,($MILLION)

FIGURE 51.INTELLIA THERAPEUTICS.: NET SALES ,($MILLION)

FIGURE 52.JUNO THERAPEUTICS, INC..: NET SALES ,($MILLION)

FIGURE 53.MERCK & CO., INC..: NET SALES ,($MILLION)

FIGURE 54.MILTENYI BIOTECH.: NET SALES ,($MILLION)

FIGURE 55.NOVARTIS AG.: NET SALES ,($MILLION)

FIGURE 56.PFIZER, INC..: NET SALES ,($MILLION)

FIGURE 57.SORRENTO THERAPEUTICS, INC..: NET SALES ,($MILLION